{"entity":{"id":"nct05938270","kind":"trial","name":"A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is completed.","summary":"The registry lists NCT05938270 as completed, last updated 2026-06-30. Enrolment is 113 actual participants. Interventions: Saruparib (AZD5305), Darolutamide, No Treatment. Primary measures include Fold change in % γH2AX positive cells from baseline value in tumour samples. No results are posted in the registry; this does not exclude separate publications.","status":"completed","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05938270","url":"https://clinicaltrials.gov/study/NCT05938270"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05938270","phase":"1","setting":"An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)","sponsor":"AstraZeneca","started":"2023-09-21","startedType":"actual","enrolled":113,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05938270/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}]}}